{
    "id": 23675,
    "fullName": "ESR1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ESR1 mutant indicates an unspecified mutation in the ESR1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "mutant",
    "createDate": "06/24/2016",
    "updateDate": "04/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11808,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor positive breast cancer xenograft model harboring an ESR1 mutation was sensitive to H3B-6545 treatment, demonstrating greater antitumor activity than when treated with Nolvadex (tamoxifen) or Faslodex (fulvestrant) (Cancer Res 2017;77(13 Suppl):Abstract nr DDT01-04).",
            "molecularProfile": {
                "id": 24391,
                "profileName": "ESR1 mutant"
            },
            "therapy": {
                "id": 6150,
                "therapyName": "H3B-6545",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9849,
                    "pubMedId": null,
                    "title": "Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/DDT01-04"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11163,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Elacestrant (RAD1901) treatment resulted in partial response in patients with ER-positive breast cancer, including those harboring ESR1 mutations (J Clin Oncol 35, 2017 (suppl; abstr 1014)).",
            "molecularProfile": {
                "id": 24391,
                "profileName": "ESR1 mutant"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9124,
                    "pubMedId": null,
                    "title": "Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_192812.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7076,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring ESR1 mutations and those who were ESR1 wild-type (PMID: 27174596).",
            "molecularProfile": {
                "id": 24391,
                "profileName": "ESR1 mutant"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6177,
                    "pubMedId": 27174596,
                    "title": "Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27174596"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12102,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR439859 inhibited Esr1 signaling and proliferation of ESR1-mutant breast cancer cell lines in culture, and resulted in tumor regression in cell line xenograft models (Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-05).",
            "molecularProfile": {
                "id": 24391,
                "profileName": "ESR1 mutant"
            },
            "therapy": {
                "id": 6293,
                "therapyName": "SAR439859",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10042,
                    "pubMedId": null,
                    "title": "Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/77/4_Supplement/P3-04-05"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7075,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Falsodex (fulvestrant) and Pictilisib (GDC-0941) combination treatment did not improve progression free survival compared to Falsodex (fulvestrant) alone in ER positive breast cancer patients harboring ESR1 mutations (PMID: 27174596).",
            "molecularProfile": {
                "id": 24391,
                "profileName": "ESR1 mutant"
            },
            "therapy": {
                "id": 4357,
                "therapyName": "Fulvestrant + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6177,
                    "pubMedId": 27174596,
                    "title": "Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27174596"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24391,
            "profileName": "ESR1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}